News >

Carfilzomib Continues to Show Frontline Potential in Myeloma

Kristi Rosa
Published: Monday, Apr 08, 2019

Carfilzomib (Kyprolis) is an agent that should be considered for use in the frontline setting for high-risk patients with multiple myeloma as induction therapy prior to early autologous stem cell transplant, said Juan P. Alderuccio, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication